Literature DB >> 20828197

Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.

Claudia Trefzer1, Monica Rengifo-Gonzalez, Marlon J Hinner, Patricia Schneider, Vadim Makarov, Stewart T Cole, Kai Johnsson.   

Abstract

Benzothiazinones (BTZs) form a new class of potent antimycobacterial agents. Although the target of BTZs has been identified as decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1), their detailed mechanism of action remains obscure. Here we demonstrate that BTZs are activated in the bacterium by reduction of an essential nitro group to a nitroso derivative, which then specifically reacts with a cysteine residue in the active site of DprE1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20828197     DOI: 10.1021/ja106357w

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  58 in total

Review 1.  The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan.

Authors:  Luke J Alderwick; James Harrison; Georgina S Lloyd; Helen L Birch
Journal:  Cold Spring Harb Perspect Med       Date:  2015-03-27       Impact factor: 6.915

Review 2.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 3.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

4.  Pseudomonas aeruginosa D-arabinofuranose biosynthetic pathway and its role in type IV pilus assembly.

Authors:  Hanjeong Harvey; Julianne V Kus; Luc Tessier; John Kelly; Lori L Burrows
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

5.  Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.

Authors:  Sarah M Batt; Talat Jabeen; Veemal Bhowruth; Lee Quill; Peter A Lund; Lothar Eggeling; Luke J Alderwick; Klaus Fütterer; Gurdyal S Besra
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

Review 6.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

7.  Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.

Authors:  Kai Lv; Xuefu You; Bin Wang; Zengquan Wei; Yun Chai; Bo Wang; Apeng Wang; Guocheng Huang; Mingliang Liu; Yu Lu
Journal:  ACS Med Chem Lett       Date:  2017-05-10       Impact factor: 4.345

8.  Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.

Authors:  Lu Xiong; Chao Gao; Yao-Jie Shi; Xin Tao; Cui-Ting Peng; Juan Rong; Kun-Lin Liu; Qian Lei; Yi-Wen Zhang; Ning-Yu Wang; Luo-Ting Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

9.  Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.

Authors:  Linhu Li; Kai Lv; Yupeng Yang; Jingquan Sun; Zeyu Tao; Apeng Wang; Bin Wang; Hongjian Wang; Yunhe Geng; Mingliang Liu; Huiyuan Guo; Yu Lu
Journal:  ACS Med Chem Lett       Date:  2018-06-26       Impact factor: 4.345

10.  Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.

Authors:  Caroline Shi-Yan Foo; Benoit Lechartier; Gaëlle S Kolly; Stefanie Boy-Röttger; João Neres; Jan Rybniker; Andréanne Lupien; Claudia Sala; Jérémie Piton; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.